The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1304
Implantable Cardioverter Defibrillators
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Implantable cardioverter defibrillators (ICDs) are widely used in patients at risk for sudden cardiac death (SCD) because these devices have been highly successful in terminating life-threatening ventricular arrhythmias and in increasing survival.1

DEVICES — Current pulse generators are implanted subcutaneously in the pectoral area with single or dual pacing/defibrillator leads placed transvenously in the atria and ventricles.They are capable not only of defibrillating (>95% success rate) but also of dual chamber physiologic pacing, remote monitoring and discriminating (not always correctly) supraventricular from ventricular arrhythmias. The usual hospital bill for implanting a typical dual chamber device is about $75,000, and most must be replaced because of battery depletion after 5-7 years.

INDICATIONS — The goal of ICD therapy is to prevent premature arrhythmic death ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Implantable Cardioverter Defibrillators
Article code: 1304b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian